Results 11 to 20 of about 1,853,915 (311)

Prediction of potential targets of aloe-emodin in the treatment of hepatocellular carcinoma using network pharmacology combined with bioinformatics. [PDF]

Discov Oncol
Background Hepatocellular carcinoma is one of the most common and malignant tumors worldwide. Although aloe-emodin (AE), a pure natural drug, can effectively kill hepatocellular carcinoma cells, its internal molecular mechanism has not been fully ...
Wei J, Chen H, Xu M, Zhang Z, Wang J, Jiang W, Zhou W, Xiong M.   +7 more
europepmc   +2 more sources

USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity. [PDF]

Clin Transl Med
Background Hepatocellular carcinoma remains one of the most lethal cancers, characterized by poor prognosis and low life expectancy. Unfortunately, there are very few molecular therapeutic options available for it.
Wang X, Su Y, Lan B, Li X, Zhang B, Zhang L, Wang Y, Zhang C, Xuan C.   +8 more
europepmc   +2 more sources

Hepatocellular carcinoma [PDF]

Nature Reviews Disease Primers, 2021
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis ...
Llovet, Josep M., Kelley, Robin Kate, Villanueva, Augusto, Singal, Amit G., Pikarsky, Eli, Roayaie, Sasan, Lencioni, Riccardo, Koike, Kazuhiko, Zucman-Rossi, Jessica, Finn, Richard S.   +9 more
openaire   +4 more sources

Hepatocellular carcinoma [PDF]

Nature Reviews Disease Primers, 2016
Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer. The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol ...
Llovet, Josep M., Zucman-Rossi, Jessica, Pikarsky, Eli, Sangro, Bruno, Schwartz, Myron, Sherman, Morris, Gores, Gregory   +6 more
  +9 more sources

Hepatocellular Carcinoma [PDF]

Current Opinion in Oncology, 2000
Hepatocellular carcinoma (HCC) is a disease that is extremely difficult to manage and is increasing markedly in incidence. This presents both an opportunity and a challenge. At-risk patients can be identified and early detection of HCC is feasible. New surgical techniques and postoperative therapies, including hepatic intra-arterial radiation, may ...
LENCIONI, RICCARDO ANTONIO, CIONI, DANIA, Bartolozzi C.   +2 more
  +14 more sources

Hepatocellular carcinoma [PDF]

British Journal of Cancer, 2001
The number of papers published regarding hepatocellular carcinoma between 1999 and 2001 increased from previous years. This year a study confirmed the increase in incidence in the United States. Also, several studies established for the first time that tobacco smoking was a risk factor for the development of this tumor. Several studies established that
Giovannini, M, Elias, D, Monges, G, Raoul, J L, Rougier, P   +4 more
openaire   +4 more sources

Resveratrol protects against chronic alcohol-induced liver disease in a rat model

STEMedicine, 2022
Hepatic ethanol metabolism participates in the pathogenesis of alcoholic liver disease (ALD). We aimed to evaluate the protecting effects and underlying mechanisms of Resveratrol against ALD.
Hanzhang Zhu, Jun Lu, Weijiang Zhou, Changku Jia   +3 more
doaj   +1 more source

CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Journal of Translational Medicine, 2023
Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence.
Chuanzheng Wang, Fei Cao, Jiahao Cao, Zhen Jiao, Yuting You, Yu Xiong, Wenxiu Zhao, Xiaomin Wang   +7 more
doaj   +1 more source

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

New England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn, S. Qin, M. Ikeda, P. Galle, M. Ducreux, Tae-You Kim, M. Kudo, V. Breder, P. Merle, A. Kaseb, Daneng Li, W. Verret, Derek-Zhen Xu, Sairy G. Hernandez, Juan Liu, Chen Huang, S. Mulla, Yulei N. Wang, Ho Yeong Lim, A. Zhu, A. Cheng   +20 more
semanticscholar   +1 more source

Heat shock protein HSPA13 promotes hepatocellular carcinoma progression by stabilizing TANK

Cell Death Discovery, 2023
HSPA13, an important member of the heat shock protein family, plays an essential role in the oncogenesis of many organs, but the mechanism and function in hepatocellular carcinoma (HCC) is still unclear.
Xuesong Cen, Yuyan Lu, Jing Lu, Changhong Luo, Ping Zhan, Yizhe Cheng, Fan Yang, Chengrong Xie, Zhenyu Yin, Fuqiang Wang   +9 more
doaj   +1 more source